DNA Damage in Healthy Individuals and Respiratory Patients after Treating Whole Blood In vitro with the Bulk and Nano Forms of NSAIDs by Mojgan Najafzadeh et al.
ORIGINAL RESEARCH
published: 28 September 2016
doi: 10.3389/fmolb.2016.00050
Frontiers in Molecular Biosciences | www.frontiersin.org 1 September 2016 | Volume 3 | Article 50
Edited by:
Luigi Bonacina,
University of Geneva, Switzerland
Reviewed by:
Sílvia Castro Coelho,
Faculdade de Engenharia da
Universidade do Porto, Portugal
Davide Staedler,
TIBIO, Switzerland
*Correspondence:
Diana Anderson
d.anderson1@bradford.ac.uk
Specialty section:
This article was submitted to
Nanobiotechnology,
a section of the journal
Frontiers in Molecular Biosciences
Received: 16 February 2016
Accepted: 23 August 2016
Published: 28 September 2016
Citation:
Najafzadeh M, Normington C,
Jacob BK, Isreb M, Gopalan RC and
Anderson D (2016) DNA Damage in
Healthy Individuals and Respiratory
Patients after Treating Whole Blood In
vitro with the Bulk and Nano Forms of
NSAIDs. Front. Mol. Biosci. 3:50.
doi: 10.3389/fmolb.2016.00050
DNA Damage in Healthy Individuals
and Respiratory Patients after
Treating Whole Blood In vitro with the
Bulk and Nano Forms of NSAIDs
Mojgan Najafzadeh 1, Charmaine Normington 1, Badie K. Jacob 2, 3, Mohammad Isreb 4,
Rajendran C. Gopalan 4 and Diana Anderson 1*
1Division of Medical Sciences, School of Life Sciences, University of Bradford, Bradford, UK, 2 Bradford Royal Infirmary,
Bradford, UK, 3 St Luke’s Hospital, Bradford, UK, 4 School of Pharmacy, University of Bradford, Bradford, UK
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzyme activity which affects
the inflammatory response. Inflammation is associated with increasing cancer incidence.
Pre-clinical and clinical studies have shown that NSAID treatment could cause an
anti-tumor effect in cancers. In the present study, blood was taken from healthy
individuals (n = 17) and patients with respiratory diseases or lung cancer (n = 36).
White blood cells (WBC) were treated with either a micro-suspension, i.e., bulk (B) or
nano-suspension (N) of aspirin (ASP) or ibuprofen (IBU) up to 500µg/ml in the comet
assay and up to 125µg/ml in themicronucleus assay. In this study results were compared
against untreated lymphocytes and their corresponding treated groups. The results
showed, that NSAIDs in their nano form significantly reduced the DNA damage in WBCs
from lung cancer patients in bulk and nano compared to untreated lymphocytes. Also,
there was a decrease in the level of DNA damage in the comet assay after treating
WBCs from healthy individuals, asthma and COPD groups with aspirin N (ASP N) but
not with IBU N. In addition, the number of micronuclei decreased after treatment with
NSAIDs in their nano form (ASP N and IBU N) in the healthy as well as in the lung cancer
group. However, this was not the case for micronucleus frequency in asthma and COPD
patients. These data show that lymphocytes from different groups respond differently to
treatment with ASP and IBU as measured by comet assay and micronucleus assay, and
that the size of the suspended particles of the drugs affects responses.
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INTRODUCTION
Extensive pre-clinical data and a limited number of clinical investigations have proposed a
direct effect of non-steroidal anti-inflammatory drugs (NSAIDs) on tumor biology, with an
anti-tumor effect on several of the hallmarks of cancer, including proliferative capacity, evasion
of apoptosis and cell cycle regulation, and invasive capability of tumor cells (Park et al., 2014).
Furthermore, clinical evidence has suggested a pertinent role in down-regulating the systemic
inflammatory response whilst favorably influencing the local inflammatory response within the
tumor microenvironment (Hussain et al., 2012). Despite such compelling results, the clinical
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applicability of NSAIDs, statins and histamine-2 receptor
antagonists has not been fully realized, particularly in patients
identified at high risk on the basis of inflammatory parameters
(Pasche, 2013). Most of the studies with NSAIDs have been
conducted with gastrointestinal cancers (colorectal, gastric,
esophagus), etc. A study examined the potential role that these
agents may play in improving survival and reducing recurrence
in patients with potentially curative colorectal cancer, with
a particular focus on their effects at the local and systemic
inflammatory response (Mansouri et al., 2013).
A clinical trial study examined the association between
developing cancer and long-term, taking of daily low-dose
aspirin (100mg) and placebo in healthy women (Cook
et al., 2013). There was no extended effect on cancer
deaths or colorectal polyps, however, the side effects of
aspirin such as gastrointestinal bleeding and peptic ulcers
were statistically noticed (Cook et al., 2013). With few
exceptions, however, epidemiological studies have found that
individuals who take NSAIDs have a reduced risk of colorectal
adenomas and carcinoma (Baron, 2009). Similarly, randomized
studies in patients with familial adenomatous polyposis have
uniformly found that NSAIDs can lead to polyp regression
and prevention of new polyps, and trials in patients with
sporadic adenomas document that aspirin reduces the risk of
adenoma recurrence. Burn et al. (2011) examined the effect of
aspirin on cancer risk in carriers of hereditary colorectal cancer
in the Colorectal Adenoma/Carcinoma Prevention Programme
(CAPP) randomized controlled trial. They concluded that 600mg
per day for a mean of 25 months reduced cancer incidence after
58 months in carriers of hereditary colon cancer (Burn et al.,
2011). They are planning studies to establish the optimum dose
and duration of treatment (Burn et al., 2011, 2013). Together
these data provide convincing evidence for the chemopreventive
efficacy of NSAIDs in the large bowel (Baron, 2009; Brady et al.,
2011; Seufert et al., 2013).
There is more evidence that shows a chemopreventive effect
for aspirin and other NSAIDs on colorectal cancer (Coghill
et al., 2012) and other cancer types such as prostate cancer
(Kawahara et al., 2010), oesophageal (Kang et al., 2013), gastric
(Tian et al., 2010), and breast (Brasky et al., 2011; Retsky et al.,
2012). The association between renal cell carcinoma and NSAIDs
is inconsistent (Liu et al., 2013).
Harris et al conducted a case control study of NSAIDs among
489 lung cancer patients and 978 control subjects. Matching
characteristics included age, gender, and pack-years of cigarette
smoking. In order to assess the effects of NSAIDs on tobacco
carcinogenesis, only heavy smokers were included in the control
group (Harris et al., 2002). The study indicated that daily intake
of NSAIDs for at least 2 years prior to interview was associated
with a 68% reduction in the relative risk of lung cancer (p< 0.01).
The inverse trend of lung cancer risk with increasing NSAID use
was highly significant (p < 0.01). Considering these results with
the molecular evidence suggested that regular NSAID intake may
prevent tobacco carcinogenesis through COX-2 blockade (Harris
et al., 2002).
The present study is also concerned with the effect of
NSAIDs in patients with other respiratory diseases. In this
study, DNA damage in peripheral lymphocytes of healthy
individuals and respiratory disease patients [asthma, chronic
obstructive pulmonary disease (COPD), and lung cancer] have
been compared before and after treatment with either the bulk
(suspension was prepared from the powders as received) and
nanoparticle versions of aspirin and ibuprofen in the single cell
gel electrophoresis (SCGE) or Comet assay (Tice et al., 2000) and
in the micronucleus assay (Fenech, 2007). Also, bulk versions of
aspirin and ibuprofen were compared directly with their nano
forms. This is the first study to our knowledge that the effects of
the particle size of these compounds have been investigated at the
cellular level ex vivo/in vitro. Our use of lymphocytes is supported
by the observations of theWHO/IPCS (Albertini et al., 2000) who
reported that lymphocytes are suitable surrogate cells for cancer,
and our further work showing that they are suitable surrogates
not only for cancer but also for other disease states (Najafzadeh
et al., 2012; Anderson et al., 2014), because DNA is the same in
all cells of an individual.
The Comet assay was used as a rapid and very sensitive
fluorescent microscopic method to assess DNA damage at the
individual cell level where broken DNA strands move toward
the anode forming a comet shape (Tice et al., 2000; Anderson
et al., 2014) and the micronucleus assay (Fenech, 2000) was
used for measuring cytogenetic damage. The study of DNA
damage at the chromosome level is an essential part of genetic
toxicology because chromosomal mutation is an important event
in carcinogenesis. The micronucleus assay has emerged as one
of the preferred methods for assessing chromosome damage
because it enables both chromosome loss and chromosome
breakage to be measured reliably. Certain chemicals can be
mutagenic and may lead to the induction of micronuclei in
cells at the interphase stage. This occurs as a consequence
of interference with chromosome structure and/or segregation
(Fenech, 2002, 2003, 2007; Kirsch-Volders et al., 2003; Fenech
et al., 2009).
There is already another but preliminary communication
which was part of this study earlier, responses of lymphocytes
after exposure to the bulk compound of ibuprofen and its
nanoparticles were investigated by the patch-clamp technique
which examines physiological changes in the ion channels of the
cell membrane (Shang et al., 2014).
MATERIALS AND METHODS
Ethical Approval
This present study was approved by Leeds (Central)
Research Ethics Committee UK (REC reference number:
09/H1313/37) and the Research Support and Governance
Office, Bradford Teaching Hospitals NHS Foundation (ReDA
number: 1202). Ethical permission was also provided by
the University of Bradford Research Ethics Sub-Committee
on Research in Human Subjects (reference number:
0405/8).
The characteristics of patients and healthy individuals are
shown in Table 1.
Whole Blood Sample Collection
The patients were from the Outpatient Respiratory Disease
Clinic of Dr. Badie K. Jacobs (St Luke’s Hospital, Bradford,
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TABLE 1 | Population characteristics.
Sample no. Age Gender Ethnicity Smoking history Cigarettes per day Years smoked Pack years
LUNG CANCER PATIENTS
1 61 M Caucasian Past smoker 20 30 30
2* 65 M Caucasian Smoker 25 40 50
3* 68 F Caucasian Past smoker 20 >20 20
4* 55 M Caucasian Smoker 20 30 30
5 63 M Caucasian Smoker 20 >40 50
6 65 M Caucasian Past smoker 15 >30 23
7 58 M Caucasian Smoker 10 30 15
8 63 F Caucasian Smoker 40 40 15
9 70 M Caucasian No 0 0 0
10 76 F Caucasian Past smoker 20 25 25
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
11* 63 M Caucasian Past smoker Pipe
12* 55 F Caucasian Smoker 20 30 30
13* 63 F Caucasian Smoker 30 30 45
14 61 M Caucasian Smoker 20 40 40
15 77 M Caucasion Smoker 20 >40 40
16* 72 F Caucasian Past smoker 20
17 78 M Caucasian Past smoker 20 >40 40
18 54 M Caucasian Smoker 5–10 30 11
19 61 M Asian Smoker 20 >30 30
20 83 M Caucasian No 0 0 0
ASTHMA
21 57 F Caucasian No 0 0 0
22 39 F Caucasian No 0 0 0
23 38 F Caucasian No 0 0 0
24* 26 M Asian No 0 0 0
25 41 F Asian No 0 0 0
26 43 F CAUCASIAN NO 0 0 0
27 63 F Caucasian No 0 0 0
28 66 F Caucasian Past smoker 20 30 30
29 43 M Asian Smoker 15 25 10
30* 47 M Caucasian No 0 0 0
HEALTHY INDIVIDUALS (NEGATIVE CONTROL)
31 68 M Caucasian Smoker 5 40 10
32 39 M Asian Smoker 5 12 3
33* 26 F Caucasian No 0 0 0
34 24 M Caucasian No 0 0 0
35* 40 M Caucasian No 0 0 0
36 28 F Asian Smoker 5 6 3
37* 42 M Asian Smoker 10 23 12
38 29 M Caucasian No 0 0 0
39 47 F Asian No 0 0 0
40 45 M Caucasian No 0 0 0
*Sample numbers with asterisks indicate that individuals who were also examined in the micronuclei assay as well as Comet assay.
UK) and healthy control individuals from the University of
Bradford, UK. The criteria for patient selection included lung
cancer (without prior chemotherapy or radiotherapy), COPD
and asthma. Exclusion criteria were anemia, other diseases beside
their respiratory condition or previous occupational exposure to
other NPs (e.g., silica or asbestos).
COPD patients were over 40 years of age with a 10 or more
pack year smoking history and a fixed spirometric ratio of FEV1
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to forced vital capacity (FVC) of <0.7 or radiological evidence of
emphysema.
Asthma patients were diagnosed by their medical practitioner.
These patients had symptoms of intermittent breathlessness,
cough and wheeze. They had less than 10 pack years history
of smoking or non-smokers. They had variable and reversible
airflow obstruction on spirometery. They also may have had
atopy such as allergic rhinitis or hay fever or high IgE with
eosinophilia.
All individuals were given an information sheet, completed a
questionnaire through interview and signed a consent form prior
to approximately 10ml peripheral blood being taken.
Non-steroidal Anti-Inflammatory Drugs
Ibuprofen USP was purchased from Albermarle Europe sprl,
(Belgium). Pharmcoat 606 (HPMC) and was kindly donated by
Shinetsu (Japan). Aspirin and sodium lauryl sulfate (SLS) were
purchased from Sigma–Aldrich, UK. Kollidon 30 (PVP K-30)
was purchased from BASF (UK). Bulk and nanosuspensions of
aspirin and ibuprofen were kindly prepared by Lena nanoceutics
(Bradford, UK).
Nanomaterial Methodology
Ibuprofen is a class II drug. This means it is very slightly
soluble in water and that the bioavailability of this drug is
limited by its dissolution rate. Improving the dissolution rate
can therefore ensure the consistency of the drug concentration
profile in the blood. Much effort has been directed recently to
improve the dissolution rate of class II drugs as their number is
predicted to increase. Nanocrystallization is one approach being
developed and offers promise. However, there are few data on the
pharmacological or toxicological effects of these forms compared
to their “bulky” micronized counterpart.
Aspirin is used in the present study to compare its effect to
Ibuprofen. Both are NSAIDs. Aspirin, however, is a class III
drug and the absorption is the rate limiting step. Nano forms
of aspirin could cross the GI tract and therefore improve its
bioavailability.
Currently both ibuprofen and aspirin are marketed as
micronized particles in tables or suspension. However, there is
work on nano forms of these drugs. Companies producing nano
forms of ibuprofen could make the claim that their drug has in
theory a more consistent bioavailability and plasma drug profile.
Suspensions of aspirin and ibuprofen with solid loads of
3 and 4% (w/w) respectively were prepared. The suspending
medium consisted of: HPMC (0.5%, w/w), polyvinylpyrrolidone
K-30 (0.5%, w/w) and sodium lauryl sulfate (0.1%, w/w)
in deionized water (Plakkot et al., 2011). The milling was
carried out using Lena nanoceutics technology DM-100 machine
(Sulaiman, 2007).
Two hundred and fifty milliliter of each suspension were
milled using 150ml of 0.2mm yttrium stabilized zirconium beads
(Glen mills, USA). The materials were recycled for 60 min in the
millingmachine before being discharged in an opaque glass bottle
and stored in the refrigerator at (4◦C) for the duration of the
experiments.
TABLE 2 | Confounding factors.
Confounding factors P-value
Smoking P < 1.001
Age P < 0.437
Ethnicity P < 1.000
Drinking habit P < 0.203
Gender P < 0.20
Zeta Potential
The zeta potential for the suspensions was determined using
Zetasizer Nano ZS (Malvern Instruments, UK). The suspensions
were diluted 1:100 using deionized water and measured at 25◦C.
Clear disposable zeta cells were used. Measurement duration was
set as automatic with a minimum of 10 runs and a maximum of
100 runs. All measurements were made in triplicate.
Particle Size Analysis
The particle size distribution of aspirin and ibuprofen nano-
suspensions were determined using the dynamic light scattering
technique of the Zetasizer Nano ZS (Malvern Instruments, UK).
Samples were measured at room temperature using disposable
sizing cuvettes. All measurements were carried out in triplicate.
The particle size of the stock suspensions were measured in
triplicate immediately after milling and then rechecked at the
end of the experiments to ensure no significant change in particle
size occurred during the various phases of the experiments. The
particle size of the bulk powder was measured using the laser
diffraction technique (Sympatec Helos, UK) (Ali et al., 2009).
Approximately 20mg of each drug were transferred into the
sample vial and the primary pressure was adjusted to 4 bars
while the feeder speed was 40 mm/s. Three samples of each drug
were measured using R2 lens (0.25/0.45, 87.5 µm). Particle size
analysis was carried out using dynamic light scattering (zetasizer)
(page 10 in the paper under the subtitle “particle size analysis”
in the method section. This involved scanning 3 samples, each
had a volume of 2–3ml of the suspension (the concentration of
the suspension was 3–4%w/w or 30–40 mg/ml. This provides
thousands if not millions of particles to be measured in each
sample. The average particle size as well as the poly dispersity
index (PDI) are provided in the paper (Table 3). Transmission
Electron Microscope (TEM) images were there just to show
examples of the shape of the particles in the suspension. The
particles are suspended in an aqueous solution of a stabilizing
polymer and a surfactant. In order to study the sample using XRD
it has to be dried which means the polymer will coat the crystals.
The amorphous nature of the polymer will create a noisy signal
in the XRD diffraction rendering it hard to interpret. This is why
no pharmaceutical paper in this area has attempted to measure
these samples using XRD. An example of such work includes
a paper comparing nano particles produced using wet milling
(the same technique in this paper) with micro-fluidic reactors
(Ali et al., 2009). The paper focused on the characterization of
the suspensions and used varieties of techniques but avoided
using FTIR and XRD for the reasons mentioned above. The effect
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TABLE 3 | Average particle size, polydispersity index, and zeta potential values of the nano-suspensions (n = 3).
Suspension name Time of measurement Average particle size (nm) Polydispersity index Zeta potential value (mV)
Ibuprofen nano-suspension 3% Before cell treatment 323 ± 6.4 0.2 ± 0.01 −2.1
After cell treatment 340 ± 1.2 0.3 ± 0.001
Apsirin nano-suspension 4% Before cell treatment 289 ± 3 0.3 ± 0.03 −6.1
After cell treatment 299 ± 6.3 0.3 ± 0.05
TABLE 4 | Average particle size (x90) and the volume mean diameter of the
bulk powder (as received) of aspirin and ibuprofen (n = 3).
Suspension name Average particle size Volume mean diameter
(µm) (µm)
Ibuprofen 52.80 ± 4.37 20.50
Apsirin 78.30 ± 0.23 44.57
of these additives however on the cells was investigated in our
control to eliminate the toxicity effect of these additives. FTIRwill
suffer from the same drawback as the signal of the water, polymer
and the surfactant will create a large noisy background.
Images obtained using TEM. Samples were prepared by
placing a drop of the suspension (Aspirin 5% w/w and Ibuprofen
4% w/w) on the TEM carbon grid. The drop was left on the grid
for 10 min then the grid was washed by dipping it in water. The
grid was floated on a drop of Uranyl acetate for 10 min them
washed again with water and left to dry. The grid was then placed
in the TEM and themagnification power was 100,000x. The beam
intensity was 40,000 KV for Ibuprofen and 60,000 KV for Aspirin
sample.
The images confirm that Aspirin crystals are slightly larger
than those of Ibuprofen as was shown by the laser diffraction
measurements. The images show some smaller particles on the
side which might be small crystals of the drugs or it could be
aggregates of the polymer used to stabilize the crystals.
Comet Assay
Comet Assay Reagents
Low-melting point agarose, NaCl, EDTA, Tris base, DMSO,
Triton X-100, NaOH, EDTA Phythaemagglutinin (PHA) (Cat
No. 10576-015) were purchased from Sigma-Aldrich Ltd.
The comet assay procedure
Forty blood samples were collected (10 asthma patients, 10
COPD patients, 10 lung cancer patients and 10 healthy
individuals from Bradford University).
Preparation of whole blood samples
The experiments were carried out on whole blood instead of
isolated lymphocytes. The blood sample from each individual was
mixed with the same volume of media (RPMI 1640) and 10%
DMSO as a cryoprotector and a chelating agent to remove iron
effectively. One milliliter of the mixture was aliquot in 1.5 ml
Eppendorfs R© and transferred to−80◦C deep freezer.
Cell treatment
Hundred microliter whole blood was incubated in each
Eppendorf with five different conditions for 30 min. The first
sample was considered as an untreated lymphocyte group
without any chemicals and 900µl RPMI. In the second sample
500µg/ml of ASP B was added to 100µl of whole blood and
RPMI to the rest of that to make 1000µl in total. In the third
sample, 100µl of whole blood was added to 500µg/ml of ASP N
and RPMI. The fourth sample, 100µl of whole blood was added
to 500µg/ml of IBU B and RPMI and finally the fifth sample
consisted of 100µl of whole blood and 500µg/ml of IBU N and
RPMI. The method used thereafter was as described by Tice et al.
(2000).
Cell scoring
Olive Tail Moment (OTM) was the method used to describe
heterogeneity within a cell population and can detect variations
in DNA distribution within the tail values; however, % Tail
DNA is considered appropriate for regulatory or inter-laboratory
comparison studies. Therefore, for all studies that involve
multiple electrophoresis runs, it is recommended that % Tail
DNA alongside OTM is used to reduce variability in the results
(Kumaravel and Jha, 2006; Kumaravel et al., 2009; Azqueta et al.,
2014). Fifty cells were scored in duplicate in each patient and
healthy individuals.
Confounding Factors
These were considered for the individuals in this assay using
Mann-Whitney test and SPSS version 21 (see later Table 2).
The Cytokinesis Block Micronucleus (CBMN) Assay
General laboratory reagents were purchased from Fisher
Scientific Co. (Itasca, IL, USA). RPMI 1640 medium (with L-
glutamine and 25 mM Hepes), Cytochalasin B (Cat No. C6762),
and mitomycin C (Cat No. M0503) were purchased from
Sigma-Aldrich (Poole, UK), penicillin-streptomycin solution
(Cat No.15140-122) were purchased from Invitrogen Ltd, UK.
Slides and coverslips were obtained from VWR international.
The Fixogum rubber cement was purchased from (Marabu,
Germany).
Micronucleus procedure
six different blood samples used in this study consisted of: 5
healthy control individual, 1 asthma patient, 1 COPD patient and
3 lung cancer patients.
Under sterile conditions, culture medium was prepared.
Streptomycin solutions were added to RPMI -1640 medium
containing 25mM HEPES and L-Glutamine, with end
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concentrations of 15 and 1%, respectively. Hundred milliliter of
this medium were aliquoted to 4.5ml into T 25 cm2 Corning
culture flasks and stored at −20◦C. The T25 cm2 flasks were
equilibrated in a 37◦C incubator (5% CO2) prior to cell
culture use.
Cell treatment
Start of culture: 500µl of blood was added to a T25 cm2
culture flask containing 4.5ml medium, followed by 100µl of
phythaemagglutinin (PHA). In the next 24 h, 125µl of test
substances were added in each flask followed by 750µl of
H2O, to give an end concentration of 125µg/ml. For the
negative control, 125µl of standard control solution was used.
Cultures were incubated at 37◦C in the presence of 5% CO2
for 44 h.
Cell scoring
Using bright-field light microscopy at 40 × magnification, slides
were scored using criteria, as recommended by Fenech et al.
(2003), Fenech (2007). Micronuclei (MNi) were scored each from
binucleated (BiNC) and mononucleated (MonoNC) cells. The
nuclear division index (NDI) was used as an indicator of the
cytotoxicity and the following calculation was used to find the
NDI: NDI= (M1+ 2(M2)+ 3 (M3) /N.
Where: M1 = mononucleated cells, M2 = binucleated cells,
M3 = multinucleated cells, N = the total number of viable cells
scored (Fenech, 2007).
Statistical tests for the Comet assay
Gaussian normality was violated for many of the scale variables
as endorsed by the Kolmogorov–Smirnov test. Therefore,
non-parametric test procedures were adopted wherever
necessary, such as the Kruskal–Wallis (K–W) and the Mann–
Whitney (M–W) tests for independent samples. When testing
intra-subject differences in DNA damage, the Wilcoxon Signed
Rank test was applied (Najafzadeh et al., 2012).
Statistical analysis for the micronucleus assay
This was carried out using the chi-square test (X2) in 1000 cells
per group to determine significant differences with p-value set at
∗p ≤ 0.05 as recommended by Fenech (2003).
RESULTS
Dose Ranging Study in Lymphocytes
Three different doses each of both the bulk and nanosuspensions,
of aspirin and ibuprofen, were used to examine genotoxic
damage with the Comet and micronucleus assays in blood
samples. These doses were 250, 500, 1000µg/ml. In this study
it was determined that 500µg/ml in the Comet assay and
250µg/ml in the micronucleus assay were optimal doses with
no cellular toxicity for the two suspensions of aspirin and
ibuprofen.
Solubility
Aspirin and ibuprofen are two NSAIDs that have different levels
of solubility. Aspirin is reported to have a solubility value of
10mg/ml and ibuprofen has a solubility value of 21mg/ml. The
concentration used in this experiment was 500µg/ml which
is below the solubility value of aspirin and higher than that
of ibuprofen. The nanosuspension of aspirin was less stable
than that of ibubrofen and was made up freshly every few
weeks.
FIGURE 1 | (A) Transmission Electron Microscope (TEM) image of aspirin nanoparticles precipitated on a carbon grid. The dark particles in the image range in size
between 50 and 200 nm. The particles appear as individual particles or clusters of small particles. The black dots are the crystals of aspirin (separate or in clusters).
The gray dots are particles that are not in focus in the image or polymer aggregates (the stabilizing excipients: polyvinylpyrrolidone K-30 and hydroxylpropyl
methylcellulose). (B) Transmission Electron Microscope image of Ibuprofen nanoparticles precipitated on a carbon grid. Ibuprofen particles are less dense and therefore
appear less dark than aspirin in the image range in size between 30 and 200 nm. The particles appear as individual particles or clusters of small particles. Ibuprofen
particles are gray as they are more transparent to the electron beam. The particles that are not in focus are either more transparent or blending in the background.
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Excipient Response
The effect of the excipients in the suspensions (bulk suspensions)
on the cells was investigated by treating with a solution
containing the same concentration of the excipient without
ibuprofen and aspirin. The results showed no significant
difference between the excipient and the untreated cells.
For the Comet and micronucleus assays in all four groups
(healthy individuals, asthma, COPD and lung cancer) bulk
forms were compared directly to their nano forms. Also all
treated samples in each group were compared to their untreated
lymphocytes.
Particle Size Analysis of Aspirin and Ibuprofen and
TEM Images
The average particle size of the nanosuspensions, their poly
dispersity indices (Pdi) and their Zeta potential are reported in
Table 3. Moreover, the average particle size and the volumemean
diameter of the bulk powder are shown in Table 4. The TEM
images of aspirin and ibuprofen are shown in Figures 1A,B.
Comet Assay
As shown in Figures 2A,B, and Tables 5A,B there were four
different groups of treatment [aspirin bulk (ASP B), aspirin nano
(ASP N), ibuprofen bulk (IBU B) and ibuprofen (IBUN) and also
an untreated lymphocyte group] in each experiment.
FIGURE 2 | (A) DNA damage measured as Olive tail moments before and
after treatment with nano and bulk forms of aspirin and ibuprofen in
lymphocytes from healthy individuals and patient groups in the Comet assay.
(B) DNA damage measured as % tail DNA before and after treatment with
nano and bulk forms of aspirin and ibuprofen in lymphocytes from healthy
individuals and patient groups in the Comet assay.
DNA damage decreased in lymphocytes from healthy
individuals, asthma, COPD and lung cancer patient groups after
treatment with aspirin nanosuspension (ASP N) and ibuprofen
nanosuspension (IBU N) compared to their bulk version (micro-
suspension) in the Comet assay (P ≤ 0.01). However, when
ASP N was compared to untreated lymphocytes in all groups
in the Comet assay, DNA damage significantly decreased in all
groups, except the asthma group. When IBU N was compared
to untreated lymphocytes, in healthy individuals and the lung
cancer group, DNA damage decreased, but increased in asthma
and COPD groups.
DNA damage in lymphocytes from healthy individuals,
asthma and COPD in the untreated lymphocyte group compared
to the cells treated with ASP B and IBU B was significantly
increased both for OTM and % tail DNA (P ≤ 0.01) except for
the lung cancer group.
In lung cancer patients after treating lymphocytes with ASP
B and IBU B the DNA damage was decreased significantly
(P ≤ 0.01) and further reduction after treatment with ASP N
(p ≤ 0.001) and IBU N (P ≤ 0.01) was noted.
Confounding Factors in the Comet Assay
The confounding factors such as gender, smoking, drinking habit,
ethnicity and age were considered, and there were no significant
differences between the results in relation to these parameters
(Table 2).
Binucleated Cells (BiNC)
For each treated group (healthy individuals, asthma, COPD,
and lung cancer (Table 6), there was generally a decrease in the
number of MNi in binucleated cells after treatment in healthy
individuals and lung cancer groups when compared to the
untreated lymphocytes. There was also a reduction in the number
of MNi with ASP N compared to the ASP B, and there was a
similar reduction in the number of MNi with IBU N compared
to IBU B between different treatment types, per group.
Mononucleated Cells (MonoNC)
These are cells which have not undergone cell division. For each
group, the number of MNi was generally higher in BiNC cells
compared to Mono NC cells.
There was a decrease in number of MNi in cells treated
with both ASP B and IBU B when compared to their
untreated lymphocytes in cancer patients and healthy individual.
Comparing the bulk and the nano forms, there was a reduction in
the number of micronuclei treated with ASP N and IBU N when
compared to their bulk forms. Overall, the data of binucleated
cells and mononucleated cells indicate that there is a reduction
in DNA damage in blood samples treated with nano forms of
aspirin and ibuprofen over their bulk counterparts. DNA damage
decreased in lymphocytes from healthy individuals, asthma,
COPD and lung cancer patient groups after treatment with ASP
N and IBU N compared to their bulk version (micro-suspension)
in both assays. However, when ASP N and IBU N were
compared to untreated lymphocytes in healthy individuals and
the lung cancer group in both assays, DNA damage significantly
decreased, but this was not the case for micronucleus frequency
in asthma and COPD patients.
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TABLE 5 | DNA damage from nano and bulk forms of aspirin and ibuprofen in the lymphocytes from patient groups and healthy individuals compared to
untreated lymphocytes in the Comet assay (Olive Tail moments, A) (%Tail DNA, B).
(A)
Study groups Untreated lymphocytes OTM ASP B OTM ASP N OTM IBU B OTM IBU N OTM
Healthy individuals 2.83 ± 0.40 3.33 ± 0.80UU 2.1 ± 0.3**‡‡ 3.97 ± 1.00 2.08 ± 0.50**
Asthma 3.03 ± 0.43 7.42 ± 0.93UU 4.02 ± 0.72** 6.21 ± 0.86 4.49 ± 0.60**
COPD 3.76 ± 0.26 4.32 ± 0.60UU 2.69 ± 0.28‡‡ 4.53 ± 0.35 3.61 ± 0.56**
Lung cancer 7.00 ± 1.30 5.37 ± 1.20§§ 4.55 ± 1.05**‡‡‡ 6.98 ± 1.74 5.78 ± 1.50**‡‡
(B)
Study groups Untreated lymphocytes %Tail DNA ASP B %Tail DNA ASP N %Tail DNA IBU B %Tail DNA IBU N %Tail DNA
Healthy individuals 9.9 ± 0.96 10.9 ± 2.05UU 8.9 ± 0.85** 10.9 ± 2.69 9.3 ± 1.50**
Asthma 14.16 ± 2.05 17.4 ± 1.41UU 13.24 ± 1.01** 15.14 ± 1.23 13.7 ± 1.97**
COPD 13.13 ± 2.15 13.6 ± 1.72UU 11.6 ± 1.70** 14.28 ± 1.13 13.47 ± 2.01**
Lung cancer 14.4 ± 2.55 13.4 ± 2.09§§ 12.07 ± 1.91**‡‡‡ 12.96 ± 3.11 12.75 ± 1.86**‡‡
Decrease in significance:
Nano suspension **P < 0.01 nano suspension compared to bulk suspension.
‡‡P < 0.01 ASP N suspension compared to untreated lymphocytes.
‡‡‡P < 0.01 IBU N suspension compared to untreated lymphocytes.
Increase in significance:
Bulk suspension UUP < 0.01 Bulk suspension compared to untreated lymphocytes except for lung cancer §§P < 0.01 Bulk suspension compared to untreated lymphocytes.
TABLE 6 | The effect of nano and bulk forms of aspirin and ibuprofen on the lymphocytes from patient groups and healthy individuals compared to
untreated lymphocytes in the micronucleus assay.
Subject Treatment % BiNC % Multi MNi in BiNC cells Mono
BiMNi BiNPB BiBuds MNi
Healthy individuals Untreated lymphocytes 50.025 ± 2.02 28.52 ± 0.56 6.00 ± 1.02 3 ± 0.02 0 0
Positive control 59.12 ± 4.07 13.49 ± 0.44 47.75 ± 0.25 1.75 ± 0.77 1.25 ± 0.5 11.75 ± 1.32
Aspirin—B 53.775 ± 2.03 24.83 ± 1.52 5.22 ± 0.16 1.25 ± 0.04 0 3.5 ± 0.02
Aspirin—N 59.55 ± 0.06 13.55 ± 1.09 4 ± 0.03 0.25 ± 0.02 0 1 ± 0.45
Ibuprofen—B 57.8 ± 1.86 15.9 ± 0.09 5.75 ± 0.14 1 ± 0.125 0 2 ± 0.02
Ibuprofen – N 54.91 ± 2.09 31.56 ± 1.62 4.5 ± 0.06 1 ± 0.4 0 1.5 ± 0.3
Asthma Untreated lymphocytes 42.04 36.16 4 0 0 0
Positive control 44.17 39.16 19 0 0 4
Aspirin—B 42.44 29.05 5 1 1 1
Aspirin—N 50.1 16.11 2 1 0 4
Ibuprofen—B 47.5 25.14 8 0 2 0
Ibuprofen—N 52.13 28.2 6 0 0 4
COPD Untreated lymphocytes 57.42 2 10 0 0 1
Positive control 25.4 0.3 17 0 2 1
Aspirin—B 48.5 0.5 13 0 0 4
Aspirin—N 45.22 0.3 10 0 0 1
Ibuprofen—B 41.43 0.2 14 0 0 9
Ibuprofen—N 45.02 0.1 16 0 0 1
Lung cancer Untreated lymphocytes 46.33 ± 4.40 35.34 ± 0.48 22.67 ± 2.06 5.21 ± 0.22 3.33 ± 1.24 14.66 ± 4.01
Positive control 44.66 ± 0.06 35.66 ± 0.02 32.33 ± 0.34 2.23 ± 0.12 5.33 ± 0.04 2.00 ± 0.01
Aspirin—B 43.33 ± 0.07 29.33 ± 0.67 15.66 ± 2.77 3.33 ± 0.08 4.66 ± 0.26 3.00 ± 0.03
Aspirin—N 45.00 ± 0.12 29.66 ± 0.27 7.66 ± 0.02 0 2.33 ± 0.33 2.6 ± 0.63
Ibuprofen—B 42.33 ± 0.34 27.33 ± 0.05 11.00 ± 0.03 2.33 ± 0.01 3.66 ± 0.04 9.33 ± 0.15
Ibuprofen—N 47.33 ± 0.01 29.00 ± 0.12 9.00 ± 0.14 1.33 ± 0.56 0 2.66 ± 0.05
BiNC, Binucleated cells, % BiNC, is % expressed out of all types of 1000 (500× 2) cells scored; MonoNC, Mononucleated cells; MultiNC, Multinucleated cells % MultiNC, is % expressed
out of all types of 500 cells scored; MNi, Micronuclei score/1000 (500 × 2) cells each of BiNC and MonoNC.
Frontiers in Molecular Biosciences | www.frontiersin.org 8 September 2016 | Volume 3 | Article 50
Najafzadeh et al. Respiratory Diseases and Nano NSAIDS
Ibuprofen Treatment in Nanoparticle and Bulk
Suspensions on Ion-Channel Activities of
Lymphocytes
With the patch-clamp technique, whole-cell current recordings
from ibuprofen -treated lymphocytes were performed. A
representative whole-cell recording obtained from the treated
lymphocytes with 500µg/ml of different treatments is presented.
When compared to untreated cells, lymphocytes treated with
IBU N had lower whole-cell currents. The current–voltage (I–
V) relationships for these recordings are shown. In the presence
of nanoparticles, the amplitude of the total current (pA/pF) was
decreased at the test potentials between −50 and +0 mV. These
whole-cell currents were consistently evoked by applying 10 mV
steps of 1000 ms duration from a hold potential of −50 to
+30mV.
DISCUSSION
With regard to the solubility of aspirin and ibuprofen, it is
well documented that the dissolution rate and extent from
nanoparticles are many times higher than that of micronized
particles. Due to the large difference in surface area between
micronized and nanoparticles the diffusion of aspirin will be
different, not to mention the possibility of nanoparticles crossing
the cell membrane before dissolution. Our results below prove
that there is a difference in response between the micronized
and nano form of aspirin. In all cases the comparison between
the two NSAIDs was the one of the aims of this project and the
results supported our expectation to the differences between the
two drugs.
Briefly, the present study has examined DNA damage in the
Comet and micronucleus assays in peripheral blood lymphocytes
of patients with respiratory diseases and healthy individuals using
the nanoparticle (NP) and bulk suspensions of the NSAIDs,
aspirin and ibuprofen. DNA damage decreased in lymphocytes
from healthy individuals, asthma, COPD and lung cancer patient
groups after treatment with ASP N and IBU N compared
to their bulk version in both assays. However, when ASP
N was compared to untreated lymphocytes in all groups in
the Comet assay, DNA damage significantly decreased in all
groups, except the asthma group. When IBU N was compared
to untreated lymphocytes, in healthy individuals and the lung
cancer group, DNA damage decreased, but increased in the
asthma and COPD groups. Similarly, when comparing the bulk
and nanosuspensions, DNA damage in the micronucleus assay
followed the same pattern as for the Comet assay, where the
nano version produced less micronuclei (MNi) than the bulk.
Frequency of micronuclei (MNi) decreased after ASP N and
IBU N in the healthy individual and lung cancer groups, and
also decreased in COPD and asthma groups except for IBU N.
Furthermore, lymphocyte responses after IBU N and IBU B were
investigated by the physiological patch-clamp technique. The
patch-clamp experiments where only IBU bulk and nano forms
have been investigated demonstrated that IBU N inhibited ion
channel activity by 20%. This study also compared bulk and nano
versions and showed that nano form produced a more marked
response (Shang et al., 2014).
Based on previous studies there is no chemopreventive agent
that has been specifically designed for lung cancer, though
there are several promising areas to investigate (Greenberg
et al., 2013). Also there are a large number of clinical and
preclinical studies that have presented strong data to show
NSAIDs could inhibit various types of cancers as described
earlier (Kawahara et al., 2010; Thapa et al., 2010; Brady et al.,
2011; Coghill et al., 2011, 2012; Retsky et al., 2012; Kang et al.,
2013; Seufert et al., 2013). NSAIDs act as inhibitors of the
cyclooxygenase (COX) enzymes which convert arachidonic acid
to prostaglandin E2. The COX enzymes play an important role
in inflammation, and a large number of COX-2 dependent
genes are involved in tumorigenesis (Kim et al., 2010; Xu et al.,
2012). COX-2 is often up-regulated in carcinoma-in-situ and
non-small cell lung cancer (Krysan et al., 2006). In a recent
study, Naproxen which is a strong NSAID was examined to
find the effects on urinary bladder cancer cells in human and
rat bladder cancers. Naproxen made an accumulation of cells
at the G1 phase mediated through CDK4, cyclin D1 and p21
and a significant apoptosis. The apoptosis largely was due to
down-regulation of Bcl-2 and up-regulation of Bax was involved
(Kim et al., 2014).
Since cancer nano therapeutics has progressed in the field of
research and development in the last decade, there is significant
anticipation that nanoparticle technologies may the key to
designing successful cancer treatment (Bertrand et al., 2014).
Inflammation is one of the critical factors in carcinogenesis,
and many investigators have focused on anti-inflammatory
agents, for instance glucocorticoids, NSAIDs, statins, and
PPARγ agonists. Although, successful chemoprevention requires
subjecting the multiple pathways to carcinogenesis with the
lowest toxicity and highest efficacy (Greenberg et al., 2013).
This molecular epidemiology approach mirrors pre-clinical
and clinical findings, with regards to NSAIDs it also provides
information on bulk vs. nano-forms of these compounds and
also shows how disease state individuals might differ in their
response.
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